

Performance to 31 March 2024

	Since inception p.a.	10 Years p.a.	7 Years p.a.	5 Years p.a.	3 Years p.a.	1 Year	6 Months	3 Months
Portfolio return (AUD)	14.3%	15.0%	15.3%	15.3%	14.3%	18.2%	11.4%	5.5%
MSCI AC World Accum Index ex-Aust (AUD)	12.3%	12.6%	12.8%	12.9%	12.7%	26.7%	18.9%	13.3%
Excess return	1.9%	2.4%	2.5%	2.4%	1.6%	-8.5%	-7.6%	-7.8%

Benchmark is MSCI All Countries World Index Ex-Australia (AS). Performance is net of investment management fees. Inception date is 18th February 2014. Numbers may not sum due to rounding. Returns assume reinvestment of distributions and are annualised for periods greater than 1 year. Past performance should not be taken as an indication of future performance.

Market commentary

Global equity markets started the year strongly, appreciating 13.3% during the first quarter (all figures are in AUD unless noted otherwise). The Australian equity market underperformed the global market, growing 5.4%.

The US equity market's strong momentum at the end of fourth quarter continued, finishing up 15.4% for the first quarter (+10.3% in local currency). The Federal Reserve (**Fed**) kept interest rates at a 23-year high of 5.25-5.50% and, while they initially suggested they may be on course to deliver three 25 basis point (bp) cuts by the end of the year, stronger-than-expected economic data has seen the expectations for rate cuts in 2024 decline. Despite the higher rate environment, there is increased market confidence that the economy will avoid a recession, and execute a 'soft landing,' driving strong gains for equities in the quarter.

From a sector standpoint, Information Technology was strongest (+17.0%), driven by AI-related beneficiaries, while sectors sensitive to economic indicators such as Financials (+14.5%), Industrials (+14.2%), and Energy (+14.9%) also performed well. Weakness was seen in Real Estate (+3.0%), as well as Utilities (+6.3%) and Materials (+8.1%). Consumer Staples (+7.3%) also continues to lag other sectors, whilst Healthcare (+12.3%) and Consumer Discretionary (+10.7%) underperformed marginally.

Fund details

Strategy FUM	\$1.5Bn
ASX Ticker	CGUN
Number of Stocks	10-15
Maximum Single Stock Weighting	10%
Maximum Cash Weighting	10%
Minimum Investment ¹	\$20,000
Investment Management Fee	1.25%
Performance Fee	Zero
APIR Code	ETLO390AU

¹ Does not apply to investments made via the ASX.

Top five holdings as at 31 March 2024

Top five	Region	Sector
Alphabet	US	Information Technology
CME Group	US	Financial Services
Microsoft	US	Information Technology
Visa	US	Financial Services
Zoetis	US	Healthcare

Please note the top five holdings of the portfolio are in alphabetical order.

Portfolio characteristics – 5 years to Mar 2024

Standard deviation	13.8%
Realised beta	1.07
Tracking error	6.4%
Upside capture ratio	1.19
Downside capture ratio	1.02

Composition of portfolio performance

	Since inception p.a.	10 Years p.a.	7 Years p.a.	5 Years p.a.	3 Years p.a.	1 Year	6 Months	3 Months
Local currency return	12.0%	12.4%	12.7%	13.6%	9.0%	15.6%	12.3%	1.1%
Currency impact	2.3%	2.6%	2.6%	1.8%	5.3%	2.5%	-1.0%	4.4%
Portfolio return (AUD)	14.3%	15.0%	15.3%	15.3%	14.3%	18.2%	11.4%	5.5%

Performance is net of investment management fees. Inception date is 18th February 2014. Numbers may not sum due to rounding. Returns assume reinvestment of distributions and are annualised for periods greater than 1 year. Past performance should not be taken as an indication of future performance. Composition of portfolio performance provides an estimate of the currency contribution to portfolio returns, and derives an indicative local currency return, for each period. The currency contribution estimate reflects the Fund's weighted currency exposure (based upon the currency in which each portfolio security is traded) and the change in the relevant foreign exchange rates, relative to the Australian Dollar, over each period.

Portfolio performance

The Claremont Global Fund appreciated 5.5% during the quarter, underperforming the broader market by 7.8%, which saw a 13.3% increase on a net basis.

Key contributors to performance for the quarter were **Microsoft** and **Alphabet**:

- **Microsoft (MSFT-US)** – the company released a strong second quarter result, ahead of consensus expectations. Revenue growth was +18%, and +16% in constant currency (up from 12% sequentially – but the Activision Blizzard acquisition added approximately 3.5%). There was broad based growth across the three segments. Within the fastest growing segment, Intelligent Cloud, Azure grew 28%, in line with the first quarter and comfortably above their 26-27% guide, with a six-point contribution from AI. The monetisation of AI may also become more material within the Office suite as the adoption of Copilot becomes more widespread.

Microsoft's operating margin increased almost 500 bps to over 43%, resulting in EPS growth of 33%. While there were positive and negative one-off impacts, overall the significant margin expansion highlighted both expense control and scaling, all while continuing to make substantial investment in a high growth business.

Looking forward, while the company has not provided full year revenue guidance for FY24, management have raised their operating margin guidance, from flat to +1 to +2%, which is impressive given over 200 basis points dilution from the Activision Blizzard acquisition, and the expected level of investment.

Management signalled the build-out of their cloud/AI infrastructure

will accelerate, with capex expected to increase sequentially from US\$11.5bn in the second quarter. We believe this will serve to further enhance Microsoft's product suite and boost their scale advantages, both of which should deepen Microsoft's competitive moat.

- **Alphabet (GOOGL-US)** – while the results were not initially well-received by the market, the company delivered a solid fourth quarter result.

Revenue growth was +13% (+13% on a constant currency basis) and accelerated from +11% growth in constant currency in the third quarter. Search delivered +13% revenue growth and YouTube revenue growth was +16%. Note Microsoft's Search and News revenue growth (ex-TAC) this quarter was +8%, so despite all the market and media noise, we saw market share gains for Google. Cloud revenue growth accelerated to +26% (from last quarter's disappointing +22%). Management mentioned they are seeing Cloud workloads benefit from the strong interest in AI.

Looking at the adjusted operating margin and backing out depreciation benefits, margins were still up almost 400 bps, with more redundancies and efficiencies/optimisation signalled. It's reassuring to see Alphabet deliver another quarter of revenue growth above expense growth. Cloud margins improved and Other Bets losses narrowed (as signalled by management last quarter).

As is the case with Microsoft, the capex requirements for cloud/AI infrastructure are going to be large, with the company spending ~US\$11bn in Q4, up from US\$8bn last quarter. Overall, we come away pleased with the result and expect them to build on this momentum into FY24.

Fund details

ARSN	166 708 792
ISIN	AU60ETLO3901
Responsible Entity	Equity Trustees
Administrator	Apex
Market Maker	Nine Mile
Custodian	JP Morgan
Currency Exposure	Unhedged
Fund Inception	18th February 2014
Buy/Sell Spread	0.10% / 0.10%

Contribution to portfolio return – Quarter March 2024 (%)

Top Three	%
Microsoft	1.32
Alphabet	1.19
Equifax	1.15
Bottom Three	%
Nike	-0.75
Zoetis	-0.69
Adobe	-0.65



Key detractors to performance for the quarter were **Nike** and **Zoetis**:

- **Nike (NKE-US)** – announced their third quarter earnings in March. Revenue was flat, in-line with guidance (compared to constant currency revenue growth this time last year of 19%), whilst good margin progression from pricing actions and lower freight costs, saw adjusted EPS up 24%.

Management’s forward-looking commentary on sales growth for 1H25 disappointed the market. But more importantly in our view, Nike have shifted their strategy, admitting that they have been overly focused on the shift to direct-to-consumer (DTC) and lost focus on sport and consumer preferences, resulting in limited innovation. Management stepped away from specific targets for DTC sales, providing further scope for growth in a more tightly managed, wholesale channel. While the potential outcome, a lower proportion of DTC sales than previously expected, is on one hand disappointing (given the benefits of direct distribution that we have discussed previously), overall, we see this shift as sensible. It results in the opportunity for better alignment with Nike’s underlying consumers – rather than a top-down imposition of a rigid financial target.

In our view, the company’s competitive advantages remain intact. Nike has an enviable position within its core markets, including incredible brand strength and a significant scale advantage (being approximately twice the size of its closest competitor). The company has an enviable track record, over the last decade, organic growth has averaged almost 10% p.a., with a ROIC of 24%. With the revised distribution strategy and renewed innovation, over the medium-term, we believe Nike can regain its former trajectory.

Whilst we have reduced our valuation, the discount to the current share price remains attractive.

- **Zoetis (ZTS-US)** – the fourth quarter result was mixed. Revenue growth was solid, up 8%, however margins were below expectations, driven by currency exposures and higher operating costs, which led to a 3% earnings miss. The company’s Companion Animal results were strong, with 10% revenue growth, while Zoetis’s slower growing Livestock division surprised to the upside, rising 5%. Looking forward to FY24, the growth guidance for certain products was softer than expected. Dermatology and Trio product sets were guided to grow mid- to-high-single-digits (a slight step down from the 8-9% growth seen in FY23).

More recently, a Wall Street Journal article highlighted anecdotal cases where there were potential adverse side-effects associated with Zoetis’s Librela, the injectable monoclonal antibody therapy for dogs

with osteoarthritis pain. Zoetis maintains the medicines are safe, and many veterinarians and pet owners have reported successful treatments with Librela. However, we do note the potential risks - beyond safety, there are is also headline risk, which could impact adoption/sales regardless of the facts - and continue to monitor developments. We do note that the product was only approved for use in the U.S. last year, however Librela has been available in Europe for almost three years, where there have been relatively low rates of reported adverse events. The company has suggested that adverse effects are within their statistical expectations. In addition, because the product is new to market, the level of first event reporting is high. There have been approximately 11 million doses administered globally, with the potential of adverse effects running at a rate of 2 per 10,000, a frequency that is categorised as ‘rare.’ The company continues to have very high expectations for Librela’s performance in the US after seeing its acceptance in Europe, Australia, and Brazil.

Portfolio additions

- **Jack Henry (JKHY-US)** – we initiated a position in Jack Henry during the March quarter (by the end of March we had established a 2% position).

The company was founded in 1976 and provides technology solutions for over 7,500 banks and credit unions in the US. They provide core bank processing for over 900 banks and 700 credit union customers, with a focus on institutions with assets less than \$50bn. They also provide over 140 complimentary products and services to nearly 6,000 other customers that do not take their core bank processing offering. These complimentary services include areas such as imaging, payments processing, information security, risk management, treasury, online and mobile banking.

With respect to financials, the business has delivered an average organic revenue growth of 8% over the last ten years, a five-year average EBIT margin of 23% and ROIC of 21%. They have a very strong business model with high recurring revenue (more than 80%), high switching costs, and large barriers to entry (technology, references, regulation). They also benefit from strong industry tailwinds, which include the ongoing move to private cloud, the secular shift from cash-to-card, the rise of e-commerce and the ever-present need for banks/credit unions to improve their efficiency and consumer experience, especially in an increasingly digital world.

We believe the current valuation looks attractive, particularly relative to the market, trading on ~1.47x the current market multiple (forward P/E) compared to its ten-year average of 1.78x.

Portfolio removals

There were no removals from the portfolio in the March quarter.

Securities movements for the quarter

Bought in	Jack Henry
Sold out	-
Increased holding	CME, Adobe, Dassault Systems, Zoetis
Decreased holding	Steris, Visa, Alphabet, Agilent , LVMH, Equifax

Contact Us



Charlie Wapshott
Head of Distribution &
Investment Specialist



Andrew Fitzpatrick
Investment Specialist

Telephone: 1300 684 537

Email: contact@claremontglobal.com.au

Address: Level 32, 1 O'Connell Street, Sydney NSW 2000 | Level 7, 171 Collins Street, Melbourne VIC 3000

Web: claremontglobal.com.au

				
Strategy Inception	Companies Held	Strategy FUM	5-year total return per annum (net)	5-year alpha per annum (net)
2011	10 - 15	\$1.5Bn	15.3%	2.4%
<small>Past performance is not a reliable indicator of future performance. Returns assume reinvestment of distributions and is net of fees.</small>				

Important information

This report has been prepared by Claremont Funds Management Pty Ltd (Investment Manager) (ACN 649 280 142, ABN 38 649 280 142, CAR No. 001289207), as investment manager for the Claremont Global Fund (ARSN 166 708 792) and Claremont Global Fund (Hedged) (ARSN 166 708 407), which are together referred to as the 'Funds'. Equity Trustees Limited (ABN 46 004 031 298, AFSL 240975) ("Equity Trustees") is the Responsible Entity of the Funds. Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615) a publicly listed company of the Australian Stock Exchange (ASX: EQT). For further information on the Funds please refer to each Fund's PDS which is available at www.claremontglobal.com.au. The Target Market Determination for the product is available at www.claremontglobal.com.au. A Target Market Determination describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed. This report may contain general advice. Any general advice provided has been prepared without taking into account your objectives, financial situation or needs. Before acting on the advice, you should consider the appropriateness of the advice with regard to your objectives, financial situation and needs. Past performance is not a reliable indicator of future performance. Future performance and return of capital is not guaranteed. The information may be confidential and is intended solely for the addressee. If you are not the intended recipient, any use, disclosure or copying of this information is unauthorised and prohibited. If you receive this e-mail in error please notify the sender and delete the e-mail (and attachments). This report may contain statements, opinions, projections, forecasts and other material (forward-looking statements), based on various assumptions. Those assumptions may or may not prove to be correct. The Investment Manager and its advisers (including all of their respective directors, consultants and/or employees, related bodies corporate and the directors, shareholders, managers, employees or agents of them) (Parties) do not make any representation as to the accuracy or likelihood of fulfilment of the forward-looking statements or any of the assumptions upon which they are based. Claremont Funds Management Pty Ltd is a wholly owned subsidiary of E&P Financial Group Limited (ABN 54 609 913 457), a signatory to the United Nations Principles for Responsible Investment (UNPRI). Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward-looking statements and the Parties assume no obligation to update that information. The Parties give no warranty, representation or guarantee as to the accuracy, completeness or reliability of the information contained in this report. The Parties do not accept, except to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in connection with, the information contained in this report. Equity Trustees nor any of its related parties, their employees or directors, provide and warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Any recipient of this report should independently satisfy themselves as to the accuracy of all information contained in this report. MSCI indices source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representation with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent. Annualised performance as at March 2024, FUM figures in AUD.

Ratings are not the only factor to be taken into account when deciding whether to invest in a financial product. Ratings can change in the future. Please refer to www.zenithpartners.com.au and www.lonsec.com.au for further information about the meaning of each rating and the rating scale. **Research ratings disclaimer**

For fund investor use only. The views expressed herein are part of a wider portfolio investment strategy and should not be considered in isolation. All figures displayed in AUD.

About Claremont Global

Claremont Global is a boutique fund manager located in Sydney, Australia. We run a high-conviction, fundamental strategy and only invest in international equities. Our evidence based and rigorous bottom-up approach allows us to identify the world's best companies. If these businesses satisfy our specific criteria and strict valuation methodology the team will consider investing in them for the long term.

Our Philosophy

Our investment philosophy can be described as buying quality growth businesses at a reasonable price. We look to acquire these securities at a discount to our estimate of their intrinsic value. We explicitly exclude more cyclical or leveraged industries including banks and resources. We invest in companies whose earnings growth drives intrinsic value, whilst their inherent quality (high margins, strong balance sheets and cash flow) will help to protect client capital in difficult markets.

INVEST ONLINE



Signatory of:



Responsible Investment Association Australasia